logo
Plus   Neg
Share
Email

ImaginAb, AstraZeneca, Pfizer, Takeda Join To Develop CD8 ImmunoPET Technology

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announced Monday that it has signed a multi-party collaboration deal with AstraZeneca Plc (AZN.L,AZN), Pfizer Inc. (PFE) and Takeda Pharmaceutical Co. Ltd. The agreement is focused on furthering the clinical development of ImaginAb's CD8 ImmunoPET technology.

Under the deal terms, the collaborators will help guide a current ImaginAb-sponsored clinical trial that aims to evaluate the utility and value of CD8 ImmunoPET in immuno-oncology drug development.

In return, the collaborators will gain early access to clinical and imaging data and collectively contribute to the post-trial data analysis.

The ImmunoPET technology uses ImaginAb's 'Minibody' platform, and targets and visualizes CD8+ T cells to provide highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient. This helps to tailor treatment quickly and specifically to the needs of that patient.

Ian Wilson, Chief Executive Officer of ImaginAb, said, " We believe that working with global leaders in immuno-oncology will help us further develop CD8 ImmunoPET as a pharmacodynamic marker for use in drug development and, in the future, as a diagnostic and predictive test for use in hospitals."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>